Expression levels of apoptosis-related proteins and Ki-67 in nasal NK/T-cell lymphoma

European Journal of Haematology

Volumn 82, Issue 1, 2009, Pages 39-45

  Yasuda, Hajime ^a   Sugimoto, Koichi ^a   Imai, Hidenori ^a   Isobe, Yasushi ^a   Sasaki, Makoto ^a   Kojima, Yuko ^a   Nakamura, Shinji ^a   Oshimi, Kazuo ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

bax; bcl 2; bcl x; ki 67; mcl 1; Nasal NK T cell lymphoma

Indexed keywords

KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MALE; NATURAL KILLER CELL; NOSE CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T CELL LYMPHOMA;

ADULT; AGED; APOPTOSIS REGULATORY PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; NOSE NEOPLASMS;

EID: 57649165403     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01152.x     Document Type: Article

References (33)

1. Kanavaros P, Lescs M, Brière J, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993 81 : 2688 95.
2. Chiang AKS, Chan ACL, Srivastava G, et al. Nasal T/natural Killer (NK)-cell lymphomas are derived from Epstein-Barr virus-infected cytotoxic lymphocytes of both NK- and T-cell lineage. Int J Cancer 1997 73 : 332 8.
3. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000 89 : 2106 16.
4. Oshimi K. Progress in understanding and managing NK-cell malignancies. Br J Haematol 2007 139 : 532 44.
5. Chim C, Ma S, Au W, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004 103 : 216 21.
6. Avilés A, Díaz NR, Neri N, et al. Angiocentric nasal T/nasal killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000 22 : 215 20.
7. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey Taiwan. Ann Oncol 2004 15 : 618 25.
8. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006 24 : 612 8.
9. Au W, Intragumtornchai T, Nakamura S, et al. Clinical and pathological differences between nasal and nasal-type NK/T cell lymphomas: a summary of 136 cases from the international T cell lymphoma (ITCL) project. Blood 2006 108 : 11. (abstract 292).
10. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997 90 : 244 51.
11. Bairey O, Zimra Y, Shaklai M, et al. Bcl-2, Bcl-x, Bax, and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 1999 5 : 2860 6.
12. Colomo L, López-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003 101 : 78 84.
13. Zhao W, Daneshpouy ME, Mounier N, et al. Prognostic significance of Bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004 103 : 695 7.
14. Ghia P, Boussiotis VA, Schultze JL, et al. Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. Blood 1998 91 : 244 51.
15. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002 99 : 1885 93.
16. Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 2002 100 : 194 9.
17. Wuillème-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005 19 : 1248 52.
18. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993 74 : 609 19.
19. Strobel T, Swanson L, Korsmeyer S, et al. Bax enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 1996 93 : 14094 9.
20. Sohn SK, Jung JT, Kim DH, et al. Prognostic significance of Bcl-2, Bax, and P53 expression in diffuse large B-cell lymphoma. Am J Hematol 2003 73 : 101 7.
21. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983 31 : 13 20.
22. Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. Blood 1988 71 : 1157 60.
23. Martin AR, Weisenburger DD, Chan WC, et al. Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 1995 85 : 3671 8.
24. Wang SA, Wang L, Hochberg EP, et al. Low histologic grade follicular lymphoma with high proliferation index. Am J Surg Pathol 2005 29 : 1490 6.
25. Lorenzen J, Liu WP, Li GD, et al. Nasal T/NK cell lymphoma: a clinico pathologic study of 30 West Chinese patients with special reference to proliferation and apoptosis. Leuk Lymphoma 1996 23 : 593 602.
26. Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of P53 overexpression. Hum Pathol 1999 30 : 849 55.
27. Bossard C, Belhadj K, Reyes F, et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007 109 : 2183 9.
28. Kim SJ, Kim BS, Choi CW, et al. Ki-67 expression is predictive of prognosis in patients with stage I/II extranodal NK/T-cell lymphoma, nasal type. Ann Oncol 2007 18 : 1382 7.
29. Jaffe ES, Harris NL, Stein H, et al. World health organization classification of tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France : IARC Press, 2001.
30. Ohsawa M, Nakatsuka S, Kanno H, et al. Immunophenotypic and genotypic characterization of nasal lymphoma with polymorphic reticulosis morphology. Int J Cancer 1999 81 : 865 70.
31. Krajewski S, Bodrug S, Gascoyne R, et al. Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 1994 145 : 515 25.
32. Ohta K, Iwai K, Kasahara Y, et al. Immunoblot analysis of cellular expression of Bcl-2 family proteins, Bcl-2, Bax, Bcl-x and Mcl-1, in human peripheral blood and lymphoid tissues. Int Immunol 1995 7 : 1817 25.
33. Gascoyne RD, Krajewska M, Krajewski S, et al. Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997 90 : 3173 8.